Rosuvastatin Dosing for Moderate-Intensity Statin Therapy

Introduction to Rosuvastatin Dosing

The American Diabetes Association recommends moderate-intensity statin therapy, defined by its ability to lower LDL cholesterol by 30-49% from baseline, for certain patient populations 1, 2, 3
The American Heart Association suggests that high-intensity statin therapy achieves ≥50% reduction in LDL cholesterol 1, 2

Moderate-intensity rosuvastatin is prescribed at doses of 5-10 mg daily, as recommended by the American College of Cardiology 1, 2, 3
High-intensity rosuvastatin is prescribed at doses of 20-40 mg daily, according to the American College of Cardiology guidelines 1, 2

The American Diabetes Association recommends primary prevention for patients with diabetes aged 40-75 years without additional ASCVD risk factors using moderate-intensity statin therapy 2, 4
Patients aged >75 years who are statin candidates but may not tolerate high-intensity therapy should receive moderate-intensity statin therapy, as suggested by the American Geriatrics Society 5, 4
Patients who cannot tolerate high-intensity statin therapy should receive moderate-intensity statin therapy, according to the American Heart Association 3

For patients who cannot tolerate the intended intensity of statin therapy, the maximum tolerated dose should be used, as recommended by the American College of Cardiology 3, 4

High-intensity rosuvastatin (20-40 mg) is recommended for patients with established ASCVD, as suggested by the American Heart Association 5, 4
Moderate-intensity rosuvastatin (5-10 mg) is recommended for patients aged 40-75 with diabetes without additional risk factors, according to the American Diabetes Association 2, 4
Moderate-intensity rosuvastatin (5-10 mg) is also recommended for patients aged >75 years who are statin candidates, as suggested by the American Geriatrics Society 5, 4
Patients with LDL-C ≥190 mg/dL should receive high-intensity rosuvastatin (20-40 mg), according to the American College of Cardiology guidelines 6

Rosuvastatin demonstrates superior LDL-C lowering compared to other statins at equivalent doses, with rosuvastatin 10 mg producing significantly greater LDL-C reduction than atorvastatin 10 mg, simvastatin 20 mg, or pravastatin 40 mg, and more patients achieving NCEP ATP III LDL-C goals, as recommended by the American College of Cardiology 7

The American Heart Association acknowledges that high-intensity rosuvastatin therapy is associated with a low incidence of myopathy (<0.1%) at recommended doses of 5-40 mg daily, and a slight increase in the risk of new-onset diabetes, particularly in patients with metabolic syndrome features, according to Trends in Cardiovascular Medicine 8